Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Session Number
Upcoming First
Relevance
Session Number
Session Datetime
Gilead Sciences Europe Ltd. - Triple-Negative Breast Cancer: : See Beyond the Negatives
(ID 145)
Time
18:45 - 20:15
MSD - Transforming the Adjuvant Treatment Paradigm in Melanoma
(ID 111)
Time
08:45 - 10:15
Myriad Genetics - Developments in precision medicine for breast and ovarian cancers
(ID 136)
Time
08:45 - 10:15
ITM Isotopen Technologien München AG - A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy
(ID 102)
Time
10:30 - 12:00
Novartis - Improving Survival Outcomes in HR+/HER2− Advanced Breast Cancer: A Biological Perspective
(ID 126)
Time
10:30 - 12:00
Merck Pfizer Alliance - Patient-focused care in a changing 1L advanced bladder cancer treatment landscape
(ID 151)
Time
10:30 - 11:45
Seagen - Navigating a new era in HER2+ metastatic breast cancer: Focus on HER2CLIMB
(ID 116)
Time
10:30 - 12:00
Advanced Accelerator Applications, a Novartis Company - Actionable Targets in Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy
(ID 141)
Time
10:30 - 12:00
Medscape - A Stepwise Approach To Managing HR+/HER2- Early Breast Cancer: From Risk Assessment To Risk Management
(ID 107)
Time
18:45 - 20:15
Illumina - Profiling Non-Small Cell Lung Cancer using Comprehensive Genomic Profiling
(ID 98)
Time
08:45 - 10:15
Astellas - The evolving landscape of advanced prostate cancer
(ID 131)
Time
18:45 - 20:15
GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience
(ID 156)
Time
17:35 - 19:05